Medical Dialogues16d
USFDA accepts GSK depemokimab applications for review for asthma, chronic rhinosinusitis
London: GSK plc has announced the US Food and Drug Administration (FDA) has accepted for review the Biologics License ...
Healio7d
Twice-yearly depemokimab for asthma tolerated well as exacerbation rates fall
Patients with asthma who used depemokimab tolerated treatment well while experiencing reductions in rates of clinically ...
Nasdaq17d
GSK: Depemokimab Shows Significant Improvements For CRSwNP Patients In Phase III Trials
(RTTNews) - GSK plc (GSK.L, GSK) announced that Depemokimab demonstrated clinically meaningful and statistically significant improvements for patients with chronic rhinosinusitis with nasal polyps ...
Benzinga.com17d
GSK's Twice-Yearly Depemokimab Reduces Nasal Polyp Size, Goes Under FDA Review
On Saturday, GSK announced full results from the ANCHOR-1 and ANCHOR-2 phase 3 trials of depemokimab versus placebo (both with the standard of care [SOC]) in adults with CRSwNP. ANCHOR-1 (N=271 ...
FierceBiotech18d
GSK gears up for depemokimab debut with twin FDA filings and phase 3 data dump
With Sunday’s Academy Awards ceremony in the rearview mirror, GSK is looking ahead to a potential blockbuster premiere of its own. The British Big Pharma has filed depemokimab for FDA approval ...
Zacks Investment Research on MSN14h
GSK Stock Recovers, Rises Around 17% YTD: Time to Buy, Sell or Hold?
GSK GSK stock has risen 16.9% year to date compared with an increase of 7.0% for the industry. The stock has also ...
Investing17d
GSK's depemokimab accepted by FDA for asthma, CRSwNP indications
According to InvestingPro analysis, GSK currently appears undervalued, suggesting potential upside for investors interested in this development. The applications pertain to the use of depemokimab ...
Investing17d
GSK reports positive phase III results for depemokimab
Depemokimab's twice-yearly dosing regimen could offer a new approach to managing this chronic condition. With annual revenues of $39.28 billion and a steady dividend yield of 4.18%, GSK ...
GlobalData on MSN17d
GSK reports positive outcomes from two Phase III trials of treatment for CRSwNP
Secondary endpoint analyses from the trials showed 'significant improvements' in patients treated with the antibody.
Investing.com UK17d
US FDA accepts GSK’s application for Depemokimab review
Investing.com -- The US Food and Drug Administration has accepted GlaxoSmithKline (NYSE: GSK )’s biologics license application for depemokimab, a monoclonal antibody targeting interleukin-5 (IL-5), ...
Investing17d
GSK’s depemokimab accepted by FDA for asthma, CRSwNP indications
According to InvestingPro analysis, GSK currently appears undervalued, suggesting potential upside for investors interested in this development. The applications pertain to the use of depemokimab as ...
pharmaphorum2d
GSK asthma hope depemokimab works in second indication
GSK's experimental IL-5 inhibitor depemokimab has shown its potential in a pair of phase 3 trials in patients with chronic rhinosinusitis with nasal polyps (CRSwNP). The company said this morning ...